Self-Study 2026 Release Bundle

Type: Bundle•Format: On-demand

The 2026 BCOP Self-Study Bundle offers 17.5 BCOP CE hours and ACPE CE hours. All Self-Study modules are on-demand and allow you to review and complete your learning at your convenience for up to one year following the release of the education.

This Self-Study Release bundle contains the following modules:

  • Module 1: Bias in Clinical Trial Enrollment: Addressing Disparities in Underserved Populations
  • Module 2: Cancer Cachexia Management (phase 2 in pipeline)
  • Module 3: Updates on Anti-HER2 Therapies in Non-Small Cell Lung Cancer
  • Module 4: Updates on Treatments for Adult Acute Lymphoblastic Leukemia
  • Module 5: Utilization of Minimal Residual Disease (MRD) in Oncology
  • Module 6: Neuroendocrine Tumors
  • Module 7: Cancer Screenings & Genetic Syndromes

The modules may be completed in any order. Each contains an ACPE Pre-Test, 3-4 articles, an ACPE and BCOP Post-Test, and a Course Evaluation. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

Get the bundle

Course Learning Objectives

UAN#: 0465-0000-26-108-H99-P

Author: Alex Vondracek, PharmD, BCPS, BCOP, ACRP-CP - Investigational Drug Clinical Pharmacy Specialist - BMT/CI

Learning Objectives

  1. Describe major sources of bias that shape who is screened, invited, and enrolled in cancer clinical trials among underserved populations
  2. Explain how common eligibility criteria and operational choices influence the representativeness of enrolled participants
  3. Analyze how underrepresentation and uneven access affect interpretation and application of trial findings in practice
  4. Evaluate practical, evidence-informed strategies to improve equitable participation in contemporary U.S. trials

UAN#: 0465-0000-26-109-H01-P

Author: Emma Sullivan, PharmD, BCOP, CPP - Clinical Pharmacist Specialist, Malignant Hematology

Learning Objectives

  1. Review current pharmacologic and nonpharmacologic therapies in the management of cancer cachexia
  2. Explain the role of biomarkers and novel targets in the pathophysiology and treatment of cancer cachexia
  3. Assess evidence supporting currently available therapies for cachexia in cancer patients
  4. Evaluate the safety and effectiveness of cancer cachexia drugs in the pipeline

UAN#: 0465-0000-26-110-H01-P

Author: Alexis H. Koon, PharmD, BCOP - Clinical Pharmacy Specialist, Sarcoma/Thoracic Oncology

Learning Objectives

  1. Review the prevalence and detection methodologies of HER2 gene expression in NSCLC
  2. Identify the place in therapy for zongertinib in HER2+ NSCLC patients
  3. Evaluate the toxicities and clinical outcomes of trastuzumab deruxtecan in HER2+ NSCLC
  4. Create a treatment plan for a patient with HER2+ NSCLC advanced or metastatic disease with progression after first-line therapy

UAN#: 0465-0000-26-111-H01-P

Author: Leah B. Galloway, PharmD, BCOP - Clinical Pharmacist Specialist, Hematology/Transplant and Cellular Therapy

Learning Objectives

  1. Evaluate the safety and efficacy of a tyrosine kinase inhibitor and blinatumomab combination in first-line treatment of Ph+ ALL
  2. Describe the role of inotuzumab and blinatumomab in older adults with newly diagnosed ALL
  3. Develop a treatment plan for newly diagnosed B-cell ALL based on recent evidence for incorporating immunotherapy
  4. Discuss the safety and efficacy of a new chimeric antigen receptor (CAR) T-cell therapy, obecabtagene autoleucel, in relapsed or refractory B-cell ALL

UAN#: 0465-0000-26-112-H01-P

Author: Jessica Zhao, PharmD, BCOP - Clinical Pharmacist Specialist, Malignant Hematology

Learning Objectives

  1. Define minimal residual disease (MRD)
  2. Describe the evolution of MRD and its relevance
  3. Assess the prognostic and predictive impact of MRD testing relative to treatment decisions
  4. Describe ongoing developments and approaches

UAN#: 0465-0000-26-113-H01-P

Author: Meera J. Patel, PharmD, BCOP - Oncology Clinical Pharmacy Specialist

Learning Objectives

  1. Recognize the degree of differentiation, grading, and location of neuroendocrine tumors to help guide treatment
  2. Understand Carcinoid syndrome and existing agents for symptomatic control of neuroendocrine tumors
  3. Apply current treatment regimens and emerging agents for treatment of extrapancreatic and pancreatic neuroendocrine tumors
  4. Differentiate adverse events and toxicity profiles of neuroendocrine tumor agents, including 177Lu-Dotatate (Lutathera) and cabozantinib

UAN#: 0465-0000-26-114-H01-P

Author: Denae Beckman, PharmD, BCOP - Clinical Oncology Pharmacist

Learning Objectives

  1. Describe hereditary cancer syndromes and associated pathogenic variants that contribute to increased cancer risk
  2. Review current recommendations for comprehensive cancer screening in individuals with hereditary or genetic syndromes
  3. Compare the clinical utility and limitations of multigene panel testing in patients with suspected genetic syndromes
  4. Analyze patient specific factors and clinical scenarios to determine if a patient should undergo germline testing
Spacer Image

Knowledge and Application Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.